Carson Wealth (CWM LLC)’s Insight Molecular Diagnostics IMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-5
Closed – – 4014
2022
Q1
$0 Hold
5
– – ﹤0.01% 3764
2021
Q4
$0 Buy
+5
New +$288 ﹤0.01% 3605
2021
Q2
$1K Hold
5
– – ﹤0.01% 2832
2021
Q1
$1K Hold
5
– – ﹤0.01% 2832
2020
Q4
$1K Hold
5
– – ﹤0.01% 2831
2020
Q3
$1K Hold
5
– – ﹤0.01% 2831
2020
Q2
$1K Hold
5
– – ﹤0.01% 2830
2020
Q1
$1K Hold
5
– – ﹤0.01% 2829
2019
Q4
$1K Hold
5
– – ﹤0.01% 2822
2019
Q3
$1K Hold
5
– – ﹤0.01% 2823
2019
Q2
$1K Hold
5
– – ﹤0.01% 2825
2019
Q1
$1K Sell
5
-11
-69% -$709 ﹤0.01% 2824
2018
Q4
$0 Hold
16
– – ﹤0.01% 2204
2018
Q3
$1K Hold
16
– – ﹤0.01% 1714
2018
Q2
$1K Buy
+16
New +$788 ﹤0.01% 1560

Other funds holding IMDX

Carson Wealth (CWM LLC)'s IMDX Position: Q2 2022 in Review

Carson Wealth (CWM LLC) sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 5 shares.

Carson Wealth (CWM LLC) first reported a position in IMDX in Q2 2018 and held it in 15 quarters. The position peaked at $1K in Q2 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Carson Wealth (CWM LLC) reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Carson Wealth (CWM LLC) sold 5 Insight Molecular Diagnostics shares in Q2 2022.
  • Carson Wealth (CWM LLC) first reported a position in Insight Molecular Diagnostics in Q2 2018 and held it in 15 quarters.
  • Carson Wealth (CWM LLC)'s Insight Molecular Diagnostics position peaked at $1K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q2 2022, filed 28 Jul 2022.